Drug Trial Radar · NCT04684940
Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors
Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Dec 10, 2020
Primary completion
Apr 20, 2026
Study completion Apr 20, 2026
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Dec 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I/II clinical study will evaluate the safety and efficacy of valoctocogene roxaparvovec in patients with severe haemophilia A and inhibitors to FVIII. Part A of the study will involve subjects who have active inhibitors to FVIII, and Part B involving subjects with a prior history of inhibitors.
Conditions
- Hemophilia A With Inhibitor
- Hemophilia A With Anti Factor VIII
Interventions
Valoctocogene roxaparvovecBiological
Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events, as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0 after administration of BMN 270.Time frame: 60 months
Locations
9 sites in 7 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
Hemocentro Da UNICAMP
Campinas, Brazil
Chaim Sheba Medical Center
Ramat Gan, Israel
Kyung Hee University Hospital at Gangdong
Seoul, South Korea
Kaohsiung Medical University - Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Ege University School of Medicine
Izmir, Turkey (Türkiye)
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.